United States Biotechnology & Medical Research

Kyverna Therapeutics Inc (KYTX)

Track

Kyverna Therapeutics Inc. has seen no insider trading activity in the last 90 days. The most recent transactions occurred in April 2026, involving proposed sales by officers and directors. Prior to this, there were various buy and sell transactions recorded throughout 2025 and early 2024.
Ticker: KYTX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Proposed sale 17 Apr 2026
Value US$1,417,057.69 | Price 230.47 | Shares 43,942
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-17 2026-04-17 PrS Proposed sale
KAREN WALKER

Officer

Officer
43,942
230.47
US$1,417,058 		43,942 230.47 US$1,417,058
2026-04-14 2026-04-14 PrS Proposed sale
KAREN WALKER

Officer

Officer
19,252
193.77
US$140,552 		19,252 193.77 US$140,552
2026-04-07 2026-04-07 PrS Proposed sale
DANIEL SPIEGELMAN

Director

Non-Executive Director
11,303
491.50
US$35,606 		11,303 491.50 US$35,606
2026-03-31 2026-03-31 PrS Proposed sale
DANIEL SPIEGELMAN

Director

Non-Executive Director
16,634
8.44
US$140,404 		16,634 8.44 US$140,404
2025-12-22 2025-12-18 B Purchase
3.7
SEIDENBERG BETH C
Non-Executive Director
133,333 +18.1%
7.50
US$999,998 		133,333 +18.1% 7.50 US$999,998
2025-12-22 2025-12-18 B Purchase
3.2
Westlake BioPartners Opportunity Fund I, L.P.
Large shareholder
133,333 +18.1%
7.50
US$999,998 		133,333 +18.1% 7.50 US$999,998
2025-12-17 2025-12-15 PlS Planned sale
Walker Karen Marie

Chief Technology Officer

Officer
23,998 -51.5%
12.20
US$292,776 		23,998 -51.5% 12.20 US$292,776
2025-12-15 2025-12-15 PrS Proposed sale
KAREN WALKER

Officer

Officer
23,998
8.78
US$210,702 		23,998 8.78 US$210,702
2024-02-14 2024-02-12 B Purchase
2.7
Bain Capital Life Sciences Investors, LLC
Large shareholder
450,000 +16.6%
22.00
US$9,900,000 		450,000 +16.6% 22.00 US$9,900,000
2024-02-14 2024-02-12 B Purchase
1.5
Vida Ventures, LLC
Large shareholder
583 +inf%
22.00
US$12,826 		583 +inf% 22.00 US$12,826
2024-02-14 2024-02-12 B Purchase
1.5
Vida Ventures, LLC
Large shareholder
252,553 +inf%
22.00
US$5,556,166 		252,553 +inf% 22.00 US$5,556,166
2024-02-13 2024-02-12 B Purchase
1.3
GILEAD SCIENCES, INC.
Large shareholder
910,000 +28.3%
22.00
US$20,020,000 		910,000 +28.3% 22.00 US$20,020,000
2024-02-12 2024-02-12 B Purchase
Northpond Ventures III GP, LLC

Former 10% Owner
450,000 +inf%
22.00
US$9,900,000 		450,000 +inf% 22.00 US$9,900,000
Explore more

More insider trading research around Kyverna Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America